Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740158 | 0.89 | ATM (0.38) | OPRM1OPRK1OPRD1BTN3A1BACE1 | |
| SCHEMBL16213520 | 0.75 | MEN1 (0.40) | BTN3A1MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL7663381 | 0.75 | TAAR1 (0.37) | BTN3A1BACE1MEN1KMT2AATM | |
| SCHEMBL4698511 | 0.75 | CYP1A2 (0.54) | — | |
| SCHEMBL3736566 | 0.74 | CYP1A2 (0.43) | OPRM1OPRK1OPRD1HPGDMEN1 | |
| SCHEMBL16213420 | 0.74 | MEN1 (0.40) | BTN3A1MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL16213419 | 0.74 | MEN1 (0.40) | BTN3A1MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL3428434 | 0.73 | ADRB2 (0.40) | — | |
| SCHEMBL3428431 | 0.73 | ADRB2 (0.40) | — | |
| SCHEMBL1845710 | 0.73 | SLC6A2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829304-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080206805-A1 | Compounds and Related Methods for Mutant p53 Reactivation | APPELLA DANIEL H | 2008-08-28 | — | — | US | disclosed |
| US-7329775-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050245616-A1 | Compounds and related methods for mutant p53 reactivation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245616-A1 | Compounds and related methods for mutant p53 reactivation | TP53, TP53BP1, MDM2 | OPRM1 4337/4885OPRK1 4148/4885OPRD1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.